XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
US Stock MarketDetailed Quotes
INCR InterCure
- 1.620
- +0.010+0.62%
Close Feb 14 16:00 ET
- 1.620
- 0.0000.00%
Post 20:01 ET
76.40MMarket Cap-4.01P/E (TTM)
1.630High1.590Low27.15KVolume1.590Open1.610Pre Close44.00KTurnover0.10%Turnover RatioLossP/E (Static)47.16MShares3.72052wk High0.59P/B42.84MFloat Cap1.17052wk Low--Dividend TTM26.44MShs Float8.770Historical High--Div YieldTTM2.48%Amplitude0.990Historical Low1.620Avg Price1Lot Size
Trending Stocks
Discussing
Many institutions are bullish! What's ahead for Chinese stocks in 2025?
Recently, institutions such as Goldman Sachs, Morgan Stanley, and Appaloosa LP have spoken positively about Chinese assets. 🎙️Discussion: 1
Popular on moomoo
Feb 13 17:34
China's asset revaluation sparks debate: What are mooers buying?
InterCure Stock Forum
Dow Jones· 1 min ago
InterCure has Secured Funding of NIS 66M to support the recovery of Nir Oz Facility
PR Newswire
NEW YORK and HERZLIYA, Israel, Dec. 20, 2024
NEWS
InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million
InterCure achieved annual revenue of NIS 356 million and adjusted EBITDA of NIS 61 million, representing 17% of revenues.
The company maintained profitability for the fourteenth and fifteenth consecutive quarters despite challenges.
InterCure continues to expand its product portfolio and dedicated medical cannabis pharmacy chain.
The company is entitled to full compensat...
No comment yet